SEC filings
Dexcom (DXCM)
Recent filings Dexcom made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0001093557All filings on SEC.gov
10-QQuarterly report
Quarterly report
Dexcom reported third-quarter 2026 revenue of $1.34 billion, up 11% year over year, with operating income of $327.2 million and net income of $275.1 million, down 3%. …
8-KCurrent report
Results of Operations and Financial Condition; Other Events
Dexcom reported third-quarter 2026 revenue of $1.344 billion, up 11% year-over-year, raised its full-year 2026 revenue and margin guidance, and announced a share repurchase program of up to $1.0 billion authorized by its board. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
DexCom, Inc. appointed Jereme Sylvain, its EVP and Chief Financial Officer, to also serve as Chief Operating Officer, effective September 14, 2026; he will oversee Dexcom's global operations and quality teams. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
DexCom, Inc. appointed Glenn S. Boehnlein to its board of directors effective September 10, 2026, expanding the board to thirteen members, and named him to its Operations & Innovation and Audit Committees. …
10-QQuarterly report
Quarterly report
Dexcom reported second-quarter 2026 revenue of $1.31 billion, up 13% from the same period in 2025, with net income of $249.1 million, up 39%, and operating income of $318.3 million, up 50%. …
8-KCurrent report
Results of Operations and Financial Condition
Dexcom reported second-quarter 2026 revenue of $1.308 billion, up 13% year over year, and GAAP net income of $249.1 million, or $0.64 per diluted share, while raising the midpoint of its full-year 2026 revenue guidance to $5.18–$5.25…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Dexcom in Readster
Add Dexcom to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.